Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab
Amgen will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014 being held 15–19 November in Chicago, including data from studies evaluating evolocumab, an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.
"We will be sharing diverse data exploring the potential clinical utility of evolocumab at this year's AHA Scientific Sessions, including multiple new analyses that examine longer-term treatment with evolocumab, the effect on different lipid parameters and the efficacy of two dosing regimens," said Sean E. Harper, M.D., Executive Vice President of R&D at Amgen. "The medical community is keenly aware of the significant unmet need for many patients with high cholesterol, and we are continuing to work with regulatory agencies on the global filing packages we have submitted, including in the US and EU."
Several of the abstracts are from the large and comprehensive evolocumab clinical trial programme, PROFICIO (Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different POpulations).
Data to be presented at the AHA Scientific Sessions 2014 include the following:
Clinical Development
• Long-Term Reduction in Lipoprotein (a) With the PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of 3278 Patients in Phase 2, 3, and Open Label Extension Studies
Abstract 15743, Abstract Poster Session, Monday, Nov. 17, 9:30-11 a.m. CST (South Hall A2 - Core 2)
• Evaluation of the Relationship Between Evolocumab 140 mg Every Two Weeks and 420 mg Monthly Dosing Regimens
Abstract 16270, Abstract Poster Session, Monday, Nov. 17, 9:30-11 a.m. CST (South Hall A2 - Core 2)
• Effects of Evolocumab Treatment on Serum Adrenal and Gonadal Hormone Levels: Results from the 52-week, Phase 3, Double-blind, Randomized, Placebo-controlled DESCARTES Study
Abstract 17005, Abstract Poster Session, Monday, Nov. 17, 9:30-11 a.m. CST (South Hall A2 - Core 2)
• Trial Assessing Long-Term Use of PCSK9 Inhibition in Patients with Genetic LDL Disorders (TAUSSIG): Efficacy and Safety in Patients with Homozygous Familial Hypercholesterolemia Receiving Lipid Apheresis
Abstract 17016, Abstract Poster Session, Tuesday, Nov. 18, 9:30-11 a.m. CST (South Hall A2 - Core 2)
• The Diagnosis of Heterozygous Familial Hypercholesterolemia: Genotype versus Phenotype
Abstract 17368, Abstract Poster Session, Tuesday, Nov. 18, 9:30-11 a.m. CST (South Hall A2 - Core 2)
• Impact of Baseline PCSK9 Levels on the Efficacy of Evolocumab, a Monoclonal Antibody Against PCSK9
Abstract 16196, Abstract Poster Session, Tuesday, Nov. 18, 3-4:30 p.m. CST (South Hall A2 - Core 2)
• Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145)
Abstract 16865, Abstract Poster Session, Tuesday, Nov. 18, 3-4:30 p.m. CST (South Hall A2 - Core 2)
Early Development
• Statin-Induced Myopathy is Mediated by Isoprenoid Depletion and is Independent of Serum Cholesterol Levels
Abstract 13907, Abstract Poster Session, Sunday, Nov. 16, 9:30-11 a.m. CST (South Hall A2 - Core 2)
• Effects of Evolocumab (AMG 145) as a Monotherapy or in Combination with Statins on Lipoprotein Particles and Subclasses
Abstract 16955, Abstract Poster Session, Wednesday, Nov. 19, 9:30-11 a.m. CST (South Hall A2 - Core 7)
Sponsored Research
• PCSK9 is Elevated in HIV+ Patients
Abstract 17751, Abstract Oral Session, Saturday, Nov. 15, 2:15-2:25 p.m. CST (Room S406A)
Observational Research
• Statin Prescription and Dose Intensity Among Elderly Medicare Beneficiaries, by CV Disease Diagnosis and Prescriber Specialty
Abstract 15677, Abstract Poster Session, Monday, Nov. 17, 9:30-11 a.m. CST (South Hall A2 - Core 2)
• Low Density Lipoprotein Cholesterol Response and Statin Persistence among Patients with High Coronary Heart Disease Risk Initiating Treatment
Abstract 18986, Abstract Poster Session, Monday, Nov. 17, 9:30-11 a.m. CST (South Hall A2 - Core 2)
Health Economics
• Work Absenteeism, Short Term Disability and Related Indirect Costs Associated with Cardiovascular Events and Related Clinical Procedures
Abstract 13352, Abstract Poster Session, Sunday, Nov. 16, 9:30-11 a.m. CST (South Hall A2 - Core 2)
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance